The biosimilars realm of oncology has been surrounded by a burst of clinical and regulatory news this week, with the read out of phase III findings and extension data, legality issues, and more. Read More >>
Pivotal trial data were presented at the 2018 ASH Annual Meeting that demonstrated promising results for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL).
Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma. View now